Stock Scorecard
Stock Summary for Pieris Pharmaceuticals Inc (PIRS) - $11.60 as of 4/25/2024 8:57:36 PM EST
Total Score
15 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for PIRS
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PIRS
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PIRS
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for PIRS
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for PIRS
Financial Details for PIRS
Company Overview |
|
---|---|
Ticker | PIRS |
Company Name | Pieris Pharmaceuticals Inc |
Country | USA |
Description | Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anti-calcium protein-based drugs in the United States. The company is headquartered in Boston, Massachusetts. |
Sector Name | TRADE & SERVICES |
Industry Name | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/8/2024 |
Stock Price History |
|
Last Day Price | 11.60 |
Last Day Price Updated | 4/25/2024 8:57:36 PM EST |
Last Day Volume | 28,382 |
Average Daily Volume | 993,143 |
52-Week High | 80.80 |
52-Week Low | 10.89 |
Last Price to 52 Week Low | 6.52% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 32.29 |
Sector PE | 39.82 |
5-Year Average PE | -204.25 |
Free Cash Flow Ratio | 0.54 |
Industry Free Cash Flow Ratio | 43.47 |
Sector Free Cash Flow Ratio | 85.20 |
Current Ratio Most Recent Quarter | 3.24 |
Total Cash Per Share | 21.35 |
Book Value Per Share Most Recent Quarter | 21.64 |
Price to Book Ratio | 0.64 |
Industry Price to Book Ratio | 8.15 |
Sector Price to Book Ratio | 8.75 |
Price to Sales Ratio Twelve Trailing Months | 0.40 |
Industry Price to Sales Ratio Twelve Trailing Months | 4.00 |
Sector Price to Sales Ratio Twelve Trailing Months | 1.87 |
Share Statistics |
|
Total Shares Outstanding | 1,236,700 |
Market Capitalization | 14,345,720 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 26.43% |
Reported EPS 12 Trailing Months | -21.60 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -0.14 |
Net Income Twelve Trailing Months | -24,541,000 |
Net Income Past Year | -24,500,000 |
Net Income Prior Year | -33,300,000 |
Quarterly Revenue Growth YOY | -77.80% |
5-Year Revenue Growth | 8.03% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 26,400,000 |
Total Cash Past Year | 26,400,000 |
Total Cash Prior Year | 54,900,000 |
Net Cash Position Most Recent Quarter | 26,400,000 |
Net Cash Position Past Year | 26,400,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 26,758,000 |
Total Stockholder Equity Prior Year | 40,498,000 |
Total Stockholder Equity Most Recent Quarter | 26,758,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.72 |
MACD Signal | -0.44 |
20-Day Bollinger Lower Band | 11.51 |
20-Day Bollinger Middle Band | 13.58 |
20-Day Bollinger Upper Band | 15.65 |
Beta | 0.50 |
RSI | 35.77 |
50-Day SMA | 23.73 |
200-Day SMA | 159.73 |
System |
|
Modified | 4/25/2024 8:59:47 AM EST |